

D25

WO D

762

XP-002101518

1/1 - (C) WPI / DERWENT
AN - 82-82639E §25!
AP - JP870021367 870218
PR - JP810021367 810218; JP870021367 870218
TI - Immuno-controlling agent - comprising trans-1-cinnamyl 4-di:phenyl:methyl:piperazine
IW - IMMUNO CONTROL AGENT COMPRISE TRANS CINNAMYL DI PHENYL METHYL PIPERAZINE
PA - (EISA) EISAI CO LTD
PN - JP57136518 A 820823 DW8239 003pp
- JP1021813B B 890424 DW8920 000pp
ORD - 1982-08-23
IC - A61K31/49 ; C07D295/02
FS - CPI
DC - B03
AB - J57136518 Immuno-controlling agent comprises trans-1-cinnamyl-4-diphenyl-methyl piperazine (Cinnalizine) of formula (I). Cinnalizine has vasospasmolytic action, cerebral vasodilator action, blood flow-improving action, cerebral blood current-increasing action. It is used to treat e.g. vertigo, headache, numbness based on cerebral blood blow dyseresthesia caused by e.g. cerebral apoplexy (encephalorrhgia, cerebral thrombus, cerebral embolus etc.), arteriosclerosis, hypertensive cerebral circulation insufficiency, caput injury sequella.
- Cinnalizine has both of immuno-increasing action and immuno-inhibiting action and may thus be used for treating diseases which may be cured by increasing or inhibiting immunoreaction on living bodies, e.g. cancer, bacterial infectious diseases, allergic diseases, rheumatism and inflammation. When administered as immuno-controlling agent, dosage is usually 10-300 mg/adult/day orally or parenterally.